Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 4/2008

01-12-2008

Imaging of integrin αvβ3 expression

Authors: Ambros J. Beer, Markus Schwaiger

Published in: Cancer and Metastasis Reviews | Issue 4/2008

Login to get access

Abstract

The integrin αvβ3 plays an important role in angiogenesis and tumor metastasis. It is expressed on activated endothelial cells as well as some tumor cells. Therefore it is a promising imaging target as a potential surrogate parameter of angiogenic activity. Molecular imaging of αvβ3 expression could potentially facilitate response evaluation of antiangiogenic drugs (e. g. bevacizumab) or aid in selecting and monitoring patients receiving humanized monoclonal antibody therapies directed against αvβ3 (EMD121974). Therefore many different approaches for imaging of αvβ3 expression have been studied in the recent years, including positron emission tomography (PET), single photon emission tomography (SPECT), magnetic resonance imaging (MRI), optical imaging and ultrasound using targeted microbubbles. While optical imaging techniques lend themselves for preclinical studies, PET and SPECT using the αvβ3 specific tracers [18F]galacto-RGD and [99mTc]NC100692 are the only techniques up to now which have been successfully used in patients. The various advantages and disadvantages of several imaging techniques will be discussed in this article.
Literature
1.
Ruoslahti, E. (1996). RGD and other recognition sequences for integrins. Annual Review of Cell and Developmental Biology, 12, 697–715.PubMed
2.
Hood, J. D., & Cheresh, D. A. (2002). Role of integrins in cell invasion and migration. Nature Reviews Cancer, 2, 91–100.PubMed
3.
Xiong, J. P., Stehle, T., Zhang, R., et al. (2002). Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg–Gly–Asp ligand. Science, 296, 151–155.PubMed
4.
Cai, W., & Chen, X. (2006). Anti-angiogenic cancer therapy based on integrin αvβ3 antagonism. Anti-Cancer Agents in Medicinal Chemistry, 6, 407–428.PubMed
5.
Hynes, R. O. (2002). A reevaluation of integrins as regulators of angiogenesis. Nature Medicine, 8, 918–921.PubMed
6.
Kerbel, R. S. (2006). Antiangiogenic therapy: A universal chemosensitization strategy for cancer? Science, 312, 1171–1175.PubMed
7.
Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 350, 2335–2342.PubMed
8.
Nabors, L. B., Mikkelsen, T., Rosenfeld, S. S., Hochberg, F., Akella, N. S., Fisher, J. D., et al. (2007). Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. Journal of Clinical Oncology, 25, 1651–1657.PubMed
9.
Jaffe, C. C. (2006). Measures of response: RECIST, WHO, and new alternatives. Journal of Clinical Oncology, 24, 3245–3251.PubMed
10.
Tortora, G., Melisi, D., & Ciardiello, F. (2004). Angiogenesis: A target for cancer therapy. Current Pharmaceutical Design, 10, 11–26.PubMed
11.
Galbraith, S. M. (2003). Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development. British Journal of Radiology, 76, 83–86.
12.
Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. New England Journal of Medicine, 285, 1182–1186.PubMed
13.
Ribatti, D., Vacca, A., & Dammacco, F. (1999). The role of the vascular phase in solid tumor growth: a historical review. Neoplasia, 1, 293–302.PubMed
14.
Risau, W. (1997). Mechanisms of angiogenesis. Nature, 386, 671–674.PubMed
15.
Ellis, L. M., Liu, W., Fan, F., Jung, Y. D., Reinmuth, N., Stoeltzing, O., et al. (2002). Synopsis of angiogenesis inhibitors in oncology. Oncology, 16, 14–22.PubMed
16.
Carmeliet, P., & Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature, 407, 249–257.PubMed
17.
Hagedorn, M., & Bikfalvi, A. (2000). Target molecules for anti-angiogenic therapy: From basic research to clinical trials. Critical Reviews in Oncology/Hematology, 34, 89–110.PubMed
18.
Kuwano, M., Fukushi, J., Okamoto, M., Nishie, A., Goto, H., Ishibashi, T., et al. (2001). Angiogenesis factors. Internal Medicine, 40, 565–572.PubMed
19.
Rundhaug, J. E. (2005). Matrix metalloproteinases and angiogenesis. Journal of Cellular and Molecular Medicine, 9, 267–285.PubMed
20.
Eliceiri, B. P., & Cheresh, D. A. (2000). Role of alpha v integrins during angiogenesis. Cancer Journal From Scientific American, 6, 245–249.
21.
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000). Vascular-specific growth factors and blood vessel formation. Nature, 407, 242–248.PubMed
22.
Carmeliet, P. (2000). Mechanisms of angiogenesis and arteriogenesis. Nature Medicine, 6, 389–395.PubMed
23.
Auguste, P., Lemiere, S., & Larrieu-Lahargue, F. (2005). Molecular mechanisms of tumor vascularization. Critical Reviews in Oncology/Hematology, 54(1), 53–61.PubMed
24.
Weber, W. A. (2006). Positron emission tomography as an imaging biomarker. Journal of Clinical Oncology, 24(20), 3282–3292.PubMed
25.
Jaffer, F. A., & Weissleder, R. (2005). Molecular imaging in the clinical arena. JAMA, 293, 855–862.PubMed
26.
Matsumoto, K., Kitamura, K., Mizuta, T., et al. (2006). Performance characteristics of a new 3-dimensional continuous-emission and spiral-transmission high sensitivity and high resolution PET camera evaluated with the NEMA NU 2-2001 standard. Journal of Nuclear Medicine, 47, 83–90.PubMed
27.
Chatziioannou, A. F. (2005). Instrumentation for molecular imaging in preclinical research: Micro-PET and Micro-SPECT. Proceedings of the American Thoracic Society, 2, 533–536.PubMed
28.
Haubner, R., Finsinger, D., & Kessler, H. (1997). Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angewandte Chemie International Edition in English, 36, 1374–1389.
29.
Haubner, R., Wester, H. J., Reuning, U., et al. (1999). Radiolabeled αvβ3 integrin antagonists: A new class of tracers for tumor targeting. Journal of Nuclear Medicine, 40, 1061–1071.PubMed
30.
Haubner, R., Wester, H. J., Weber, W. A., et al. (2001). Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Research, 61, 1781–1785.PubMed
31.
Haubner, R. (2006). αvβ3-Integrin imaging: A new approach to characterise angiogenesis? European Journal of Nuclear Medicine and Molecular Imaging, 33, 54–63.PubMed
32.
Harris, J. M., Martin, N. E., & Modi, M. (2001). PEGylation: A novel process for modifying pharmacokinetics. Clinical Pharmacokinetics, 40, 539–551.PubMed
33.
Chen, X., Park, R., Shahinian, A. H., et al. (2004). Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nuclear Medicine and Biology, 31, 11–19.PubMed
34.
van Hagen, P. M., Breeman, W. A., Bernard, H. F., et al. (2000). Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. International Journal of Cancer, 90, 186–198.
35.
Bach-Gansmo, T., Danielsson, R., Saracco, A., Wilczek, B., Bogsrud, T. V., Fangberget, A., et al. (2006). Integrin receptor imaging of breast cancer: A proof-of-concept study to evaluate 99mTc-NC100692. Journal of Nuclear Medicine, 47(9), 1434–1439.PubMed
36.
Cai, W., Wu, Y., Chen, K., Cao, Q., Tice, D. A., & Chen, X. (2006). In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin αvβ3. Cancer Research, 66, 9673–9681.PubMed
37.
Haubner, R., Wester, H. J., Burkhart, F., Senekowitsch-Schmidtke, R., Weber, W., Goodman, S. L., et al. (2001). Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. Journal of Nuclear Medicine, 42, 326–336.PubMed
38.
Haubner, R., Kuhnast, B., Mang, C., Weber, W. A., Kessler, H., Wester, H. J., et al. (2004). [18F]Galacto-RGD: Synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjugate Chemistry, 15, 61–69.PubMed
39.
Felding-Habermann, B., Mueller, B. M., Romerdahl, C. A., & Cheresh, D. A. (1992). Involvement of integrin av gene expression in human melanoma tumorigenicity. Journal of Clinical Investigation, 89, 2018–2022.PubMed
40.
Haubner, R., Weber, W. A., Beer, A. J., Vabuliene, E., Reim, D., Sarbia, M., et al. (2005). Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Medicine, 2(3), e70.PubMed
41.
Myoken, Y., Kayada, Y., Okamoto, T., Kan, M., Sato, G. H., & Sato, J. D. (1991). Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites. Proceedings of the National Academy of Sciences of the United States of America, 88, 5818–5823.
42.
Bergers, G., Javaherian, K., Lo, K. M., Folkman, J., & Hanahan, D. (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science, 284, 808–812.PubMed
43.
Pichler, B., Braumueller, H., Haubner, R., Sakrauski, A. K., Kneilling, M., Senekowitsch-Schmidtke, R., et al. (2002). Monitoring of cellular immunotherapy in RIP1-Tag2 transgenic mice with radiolabelled RGD-peptides. Journal of Nuclear Medicine, 43, 122, (abstract).
44.
Boturyn, D., Coll, J. L., Garanger, E., Favrot, M. C., & Dumy, P. (2004). Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. Journal of the American Chemical Society, 126, 5730–5739.PubMed
45.
Goel, A., Baranowska-Kortylewicz, J., Hinrichs, S. H., Wisecarver, J., Pavlinkova, G., Augustine, S., et al. (2001). 99mTc-labeled divalent and tetravalent CC49 single-chain Fv’s: Novel imaging agents for rapid in vivo localization of human colon carcinoma. Journal of Nuclear Medicine, 42, 1519–1527.PubMed
46.
Chen, X., Tohme, M., Park, R., Hou, Y., Bading, J. R., & Conti, P. S. (2004). Micro-PET imaging of αvβ3-integrin expression with 18F-labeled dimeric RGD peptide. Molecular Imaging, 3, 96–104.PubMed
47.
Zhang, X., Xiong, Z., Wu, X., et al. (2006). Quantitative PET imaging of tumor integrin αvβ3 expression with 18F-FRGD2. Journal of Nuclear Medicine, 47, 113–121.PubMed
48.
Chen, X., Park, R., Tohme, M., Shahinian, A. H., Bading, J. R., & Conti, P. S. (2004). MicroPET and autoradiographic imaging of breast cancer av-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjugate Chemistry, 15, 41–49.PubMed
49.
Chen, X., Hou, Y., Tohme, M., et al. (2004). PEGylated Arg–Gly–Asp peptide: 64Cu labeling and PET imaging of brain tumor αvβ3-integrin expression. Journal of Nuclear Medicine, 45, 1776–1783.PubMed
50.
Chen, X., Liu, S., Hou, Y., et al. (2004). MicroPET imaging of breast cancer av-integrin expression with 64Cu-labeled dimeric RGD peptides. Molecular Imaging and Biology, 6, 350–359.PubMed
51.
Wu, Y., Zhang, X., Xiong, Z., et al. (2005). MicroPET imaging of glioma av-integrin expression using 64Cu-labeled tetrameric RGD peptide. Journal of Nuclear Medicine, 46, 1707–1718.PubMed
52.
Thumshirn, G., Hersel, U., Goodman, S. L., & Kessler, H. (2003). Multimeric cyclic RGD peptides as potential tools for tumor targeting: Solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry, 9, 2717–2725.PubMed
53.
Poethko, T., Schottelius, M., Thumshirn, G., Hersel, U., Herz, M., Henriksen, G., et al. (2004). Two-step methodology for high-yield routine radiohalogenation of peptides: 18F-labeled RGD and octreotide analogs. Journal of Nuclear Medicine, 45, 892–902.PubMed
54.
Poethko, T., Schottelius, M., Thumshirn, G., Herz, M., Haubner, R., Henriksen, G., et al. (2004). Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochimica Acta, 92, 317–327.
55.
Montet, X., Montet-Abou, K., Reynolds, F., et al. (2006). Nanoparticle imaging of integrins on tumor cells. Neoplasia, 8(3), 214–222.PubMed
56.
Hu, G., Lijowski, M., Zhang, H., et al. (2007). Imaging of Vx-2 rabbit tumors with αvβ3- integrin-targeted 111In nanoparticles. International Journal of Cancer, 120, 1951–1957.
57.
Balasubramanian, K., & Burghard, M. (2005). Chemically functionalized carbon nanotubes. Small, 1, 180–192.PubMed
58.
Lacerda, L., Bianco, A., Prato, M., & Kostarelos, K. (2006). Carbon nanotubes as nanomedicines: From toxicology to pharmacology. Advanced Drug Delivery Reviews, 58, 1460–1470.PubMed
59.
Liu, Z., Cai, W., He, L., et al. (2007). In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nature Nanotechnology, 2, 47–52.PubMed
60.
Singh, R., Pantarotto, D., Lacerda, L., et al. (2006). Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proceedings of the National Academy of Sciences of the United States of America, 103, 3357–3362.PubMed
61.
McDevitt, M. R., Chattopadhyay, D., Kappel, B. J., et al. (2007). Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. Journal of Nuclear Medicine, 48, 1180–1189.PubMed
62.
Caliceti, P., & Veronese, F. M. (2003). Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates. Advanced Drug Delivery Reviews, 55, 1261–1277.PubMed
63.
Wu, A. M., & Senter, P. D. (2005). Arming antibodies: Prospects and challenges for immunoconjugates. Nature Biotechnology, 23, 1137–1146.PubMed
64.
Introcaso, C. E., Hivnor, C., Cowper, S., & Werth, V. P. (2007). Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: A case series of nine patients and review of the literature. International Journal of Dermatology, 46(5), 447–452.PubMed
65.
Miller, J. C., Pien, H. H., Sahani, D., et al. (2005). Imaging angiogenesis: Applications and potential for drug development. Journal of the National Cancer Institute, 97(3), 172–187.PubMedCrossRef
66.
Spuentrup, E., & Botnar, R. M. (2006). Coronary magnetic resonance imaging: Visualization of vessel lumen and the vessel wall and molecular imaging of arteriotrombosis. European Radiology, 16, 1–14.PubMed
67.
Jaffer, F. A., & Weissleder, R. (2004). Seeing within: Molecular imaging of the cardiovascular system. Circulation Research, 94, 433–445.PubMed
68.
Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., & Li, K. C. (1998). Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging. Nature Medicine, 4, 623–626.PubMed
69.
Winter, P. M., Caruthers, S. D., Kassner, A., et al. (2003). Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel αvβ3-targeted nanoparticle and 1.5 Tesla magnetic resonance imaging. Cancer Research, 63, 5838–5843.PubMed
70.
Schmieder, A. H., Winter, P. M., Caruthers, S. D., et al. (2005). Molecular MR imaging of melanoma angiogenesis with αvβ3-targeted paramagnetic nanoparticles. Magnetic Resonance in Medicine, 53, 621–627.PubMed
71.
Thorek, D. L., Chen, A. K., Czupryna, J., & Tsourkas, A. (2006). Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Annals of Biomedical Engineering, 34, 23–38.PubMed
72.
Zhang, C., Jugold, M., Woenne, E. C., et al. (2007). Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Research, 67, 1555–1562.PubMed
73.
Daldrup-Link, H. E., Simon, G. H., & Brasch, R. C. (2006). Imaging of tumor angiogenesis: Current approaches and future prospects. Current Pharmaceutical Design, 12, 2661–2672.PubMed
74.
McDonald, D. M., & Choyke, P. L. (2003). Imaging of angiogenesis: From microscope to clinic. Nature Medicine, 9(6), 713–725.PubMed
75.
Bloch, S. H., Dayton, P. A., & Ferrara, K. W. (2004). Targeted imaging using ultrasound contrast agents. Progress and opportunities for clinical and research applications. IEEE Engineering in Medicine and Biology Magazine, 23, 18–29.PubMed
76.
Kaufmann, B. A., & Lindner, J. R. (2007). Molecular imaging with targeted contrast ultrasound. Current Opinion in Biotechnology, 18, 11–16.PubMed
77.
Ellegala, D. B., Leong-Poi, H., Carpenter, J. E., et al. (2003). Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to αvβ3. Circulation, 108, 336–341.PubMed
78.
Kumar, C. C., Nie, H., Rogers, C. P., et al. (1997). Biochemical characterization of the binding of echistatin to integrin αvβ3 receptor. Journal of Pharmacology and Experimental Therapeutics, 283, 843–853.PubMed
79.
Hughes, M. S., Marsh, J. N., Zhang, H., et al. (2006). Characterization of digital waveforms using thermodynamic analogs: Detection of contrast-targeted tissue in vivo. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 53, 1609–1616.PubMed
80.
Marsh, J. N., Partlow, K. C., Abendschein, D. R., Scott, M. J., Lanza, G. M., & Wickline, S. A. (2007). Molecular imaging with targeted perfluorocarbon nanoparticles: Quantification of the concentration dependence of contrast enhancement for binding to sparse cellular epitopes. Ultrasound in Medicine & Biology, 33(6), 950–958.
81.
Ntziachristos, V., Yodh, A., Schnall, M., et al. (2000). Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proceedings of the National Academy of Sciences of the United States of America, 97, 2767–2772.PubMed
82.
Cuccia, D. J., Bevilacqua, F., Durkin, A. J., et al. (2003). In vivo quantification of optical contrast agent dynamics in rat tumors by use of diffuse optical spectroscopy with magnetic resonance imaging coregistration. Applied Optics, 42, 2940–2950.PubMed
83.
Bremer, C., Bredow, S., Mahmood, U., et al. (2001). Optical imaging of matrix metalloproteinase-2 activity in tumors: Feasibility study in a mouse model. Radiology, 221, 523–529.PubMed
84.
Chen, X., Conti, P. S., & Moats, R. A. (2004). In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Research, 64(21), 8009–8014.PubMed
85.
Jin, Z. H., Josserand, V., Foillard, S., Boturyn, D., Dumy, P., Favrot, M. C., et al. (2007). In vivo optical imaging of integrin alphaV-beta3 in mice using multivalent or monovalent cRGD targeting vectors. Molecular Cancer, 6, 41.PubMed
86.
von Wallbrunn, A., Holtke, C., Zuhlsdorf, M., Heindel, W., Schafers, M., & Bremer, C. (2007). In vivo imaging of integrin alpha v beta 3 expression using fluorescence-mediated tomography. European Journal of Nuclear Medicine and Molecular Imaging, 34(5), 745–754, Epub 2006 Nov 28.
87.
Cai, W., Hsu, A. R., Li, Z. B., & Chen, X. (2007). Are quantum dots ready for in vivo imaging in human subjects? Nanoscale Research Letters, 2, 265–281.
88.
Michalet, X., Pinaud, F. F., Bentolila, L. A., et al. (2005). Quantum dots for live cells, in vivo imaging, and diagnostics. Science, 307, 538–544.PubMed
89.
Medintz, I. L., Uyeda, H. T., Goldman, E. R., & Mattoussi, H. (2005). Quantum dot bioconjugates for imaging, labelling and sensing. Nature Materials, 4, 435–446.PubMed
90.
Cai, W., Shin, D. W., Chen, K., et al. (2006). Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Letters, 6, 669–676.PubMed
91.
Levenson, R. M. (2004). Spectral imaging and pathology: Seeing more. Laboratory Medicine, 35, 244–251.
92.
Mansfield, J. R., Gossage, K. W., Hoyt, C. C., & Levenson, R. M. (2005). Autofluorescence removal, multiplexing, and automated analysis methods for in-vivo fluorescence imaging. Journal of Biomedical Optics, 10, 41207.PubMed
93.
Zimmer, J. P., Kim, S. W., Ohnishi, S., Tanaka, E., Frangioni, J. V., & Bawendi, M. G. (2006). Size series of small indium arsenide-zinc selenide core-shell nanocrystals and application to in vivo imaging. Journal of the American Chemical Society, 128, 2526–2527.PubMed
94.
Pradhan, N., Battaglia, D. M., Liu, Y., & Peng, X. (2007). Efficient, stable, small, and water-soluble doped ZnSe nanocrystal emitters as non-cadmium biomedical labels. Nano Letters, 7, 312–317.PubMed
95.
Mulder, W. J., Koole, R., Brandwijk, R. J., et al. (2006). Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Letters, 6, 1–6.PubMed
96.
Beer, A. J., Haubner, R., Goebel, M., et al. (2005). Biodistribution and pharmacokinetics of the αvβ3 selective tracer 18F Galacto-RGD in cancer patients. Journal of Nuclear Medicine, 46, 1333–1341.PubMed
97.
Beer, A. J., Haubner, R., Wolf, I., et al. (2006). PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. Journal of Nuclear Medicine, 47, 763–769.PubMed
98.
Stangier, I., Wester, H. J., Schwaiger, M., & Beer, A. J. (2007). Comparison of standardised uptake values and distribution volume for imaging of avz3 expression in breast cancer patients with [18F]Galacto-RGD PET. Journal of Nuclear Medicine, 48(S2), 406, (abstract).
99.
Beer, A. J., Haubner, R., Sarbia, M., Goebel, M., Luderschmidt, S., Grosu, A. L., et al. (2006). Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin αvβ3 expression in man. Clinical Cancer Research, 12(13), 3942–3949.PubMed
100.
Beer, A. J., Grosu, A. L., Carlsen, J., Kolk, A., Sarbia, M., Stangier, I., et al. (2007). [18F]Galacto-RGD PET for imaging of αvβ3 expression on neovasculature in patients with squamous cell carcinoma of the head and neck. Clinical Cancer Research, 13, 6610–6616.PubMed
101.
Beer, A. J., Lorenzen, S., Metz, S., Wester, H. J., & Schwaiger, M. (2007). Integrin avz3 expression and glucose metabolism do not correlate in primary and metastatic lesions in cancer patients: A PET study using [18F]Galacto-RGD and [18F]FDG. Journal of Nuclear Medicine, 48(S2), 30, (abstract).
Metadata
Title
Imaging of integrin αvβ3 expression
Authors
Ambros J. Beer
Markus Schwaiger
Publication date
01-12-2008
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 4/2008
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-008-9158-3

Other articles of this Issue 4/2008

Cancer and Metastasis Reviews 4/2008 Go to the issue

NON-THEMATIC REVIEW

Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents

Acknowledgments

Biography - Anthony F. Shields, M.D., Ph.D.

NON-THEMATIC REVIEW

Cell cycle control and adhesion signaling pathways in the development of metastatic melanoma

OriginalPaper

The role of DNA synthesis imaging in cancer in the era of targeted therapeutics

EditorialNotes

Preface-imaging in cancer

NON-THEMATIC REVIEW

The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits